Vivani Medical Reports First Quarter 2026 Financial Results and Provides Business Update
Insider Buying: Vivani Medical (NASDAQ:VANI) Director Purchases $1,999,999.26 in Stock
Vivani Medical, Inc. (NASDAQ:VANI) Short Interest Up 65.0% in March
Critical Survey: Verrica Pharmaceuticals (NASDAQ:VRCA) vs. Vivani Medical (NASDAQ:VANI)
Vivani Medical (VANI) Upgraded to Buy: What Does It Mean for the Stock?
Vivani Medical Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Vivani Medical (VANI) Projected to Post Quarterly Earnings on Monday
Short Interest in Vivani Medical, Inc. (NASDAQ:VANI) Decreases By 25.4%
Contrasting Vivani Medical (NASDAQ:VANI) & VYNE Therapeutics (NASDAQ:VYNE)
First Look: WBD waiver; Ackman's Meta bet; Ford-China JV
Vivani Medical, Inc. (NASDAQ:VANI) Short Interest Update
Vivani Subsidiary Cortigent Presents Promising 6-Year Early Feasibility Study Results for the Orion System at NANS 2026
Vivani Medical, Inc. Announces Closing of Common Stock Offering
Vivani Medical, Inc. Announces Pricing of Common Stock Offering
Gregg Williams Purchases 1,737,765 Shares of Vivani Medical (NASDAQ:VANI) Stock
Vivani Medical Provides Business Update and Reports Third Quarter 2025 Financial Results
Vivani Medical, Inc. Announces Closing of Common Stock Offering
Insiders Are Buying These 3 Stocks Hand Over Fist
Vivani Medical, Inc. Announces Pricing of Common Stock Offering
Vivani Medical Withdraws Record Date for Cortigent Neuromodulation Subsidiary Spin-Off
Vivani Medical to Present at the Emerging Growth Conference on September 25, 2025
Vivani Medical Announces Record Date for Spin-off of Cortigent Neuromodulation Subsidiary to Shareholders
Vivani Medical Provides Update on Clinical Development Plans for NPM-139 Semaglutide Implant for Chronic Weight Management
Vivani Medical CEO Adam Mendelsohn to Present at the H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025
Vivani Medical Provides Business Update Including $10M Equity Financing and Reports Second Quarter 2025 Financial Results
Vivani Stock Gains After Announcing Spin-Off Plans for Cortigent Unit
I Missed The Quantum Rally - I Won't Miss The Next One
Vivani Medical Provides Business Update Including $3M Equity Financing and Reports First Quarter 2025 Financial Results
Vivani Medical to Present at the American Association of Pharmaceutical Scientists' “Beyond GLP1s: Where the Science will Take Business Next” Virtual Workshop
Vivani Medical and Okava Expand Collaboration to Develop OKV-119 for Dogs, Targeting Metabolic Health and Longevity
Vivani Medical Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
Vivani Medical Announces $8.25M Private Placement Equity Financing
Vivani Medical Announces Positive Preclinical Weight Loss Data for NPM-139 Semaglutide Implant, with Potential for Once-Yearly Dosing
Vivani Medical to Present at the Emerging Growth Conference on March 27, 2025
What Makes Vivani Medical (VANI) a New Buy Stock
Vivani Medical Achieves First Implant and Full Enrollment in the First-in-Human Clinical Trial of GLP-1 Implant NPM-115 in Obese or Overweight Adults
Vivani Medical Announces Intent to Spin Off Cortigent Neurostimulation Business
EXCLUSIVE: Vivani Medical To Spin Off Cortigent Neurostimulation Business To Create Better Focus On Individual Entities And Shareholder Value
Vivani reports start of first human trial of GLP-1 implant, says H.C. Wainwright
Vivani Medical Announces Initiation of First in Human Clinical Trial with GLP-1 Implant in Obese and Overweight Individuals in Australia
Vivani Medical to Present at the Innovation in Obesity Therapeutics Summit West Coast
Vivani Medical Receives Regulatory Approval to Initiate First in Human Clinical Trial with GLP-1 Implant in Obese and Overweight Individuals in Australia
Vivani Medical to Present at the Emerging Growth Conference on September 25, 2024
Vivani Medical to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
Vivani Medical Announces FDA Clears Investigational New Drug Application and Lifts Clinical Hold for NPM-119, a Miniature Long-Term Subdermal GLP-1 Drug Implant
Vivani Medical Announces Publication of Positive Weight Loss Data Supporting Potential Veterinary Use of OKV-119 Miniature, Long-term GLP-1 Implant
VANI Stock Earnings: Vivani Medical Meets EPS for Q1 2024
Vivani Medical Provides Business Update and Reports First Quarter 2024 Financial Results
Vivani Medical Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
Vivani Medical Appoints Daniel Bradbury to its Board of Directors